Back |
home / stock / mrtx / mrtx message board
Subject | By | Source | When |
---|---|---|---|
I'm in !!!!! Glta | omri | investorshub | 09/15/2017 2:50:07 PM |
Looking good.. | Tdash | investorshub | 09/15/2017 2:38:51 PM |
preliminary on going phase II results.... much more | crudeoil24 | investorshub | 09/15/2017 12:50:30 PM |
Exactly! Do not hold over night for most | crudeoil24 | investorshub | 09/15/2017 12:45:08 PM |
Easy new comers don't get caught bag holding. | jones99 | investorshub | 09/15/2017 9:12:33 AM |
Yes no DD except the technicals were signaling | swampboots | investorshub | 09/23/2016 10:46:12 PM |
Yeah but didn't catch the high or near | girlfriend | investorshub | 09/23/2016 10:09:41 PM |
Nice out! | swampboots | investorshub | 09/23/2016 9:50:32 PM |
$MRTX looking good this morn out some at | girlfriend | investorshub | 09/22/2016 3:25:21 PM |
I will take a look thanks. | girlfriend | investorshub | 09/21/2016 7:21:24 PM |
You too! | Klinsmann | investorshub | 09/21/2016 7:10:05 PM |
I hear you.looks like $MRTX continuing here. | girlfriend | investorshub | 09/21/2016 6:58:44 PM |
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...